首頁 › 血液癌症 › 猶他州 › Salt Lake City
Salt Lake City, UT 的 血液癌症 臨床試驗
8 項針對 血液癌症 的研究正在 Salt Lake City（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
招募中2 期
- Huntsman Cancer Institute - University of Utah Health, Salt Lake City
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
招募中觀察性研究
- University of Utah, Salt Lake City
Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
招募中觀察性研究
- Primary Children's Hospital, Salt Lake City
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
招募中觀察性研究
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
招募中1 期
- University of Utah, Salt Lake City
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
招募中3 期
- Primary Children's Hospital, Salt Lake City
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
招募中1/2 期
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
招募中1 期
- Primary Children's Hospital, Salt Lake City
其他城市的 血液癌症 試驗
- Houston, TX46 項研究
- New York City, NY26 項研究
- Boston, MA25 項研究
- Washington, DC19 項研究
- Seattle, WA18 項研究
- Baltimore, MD18 項研究
- Los Angeles, CA17 項研究
- Durham, NC16 項研究
- Chicago, IL15 項研究
- Philadelphia, PA14 項研究
- Edison, NJ13 項研究
- Nashville, TN13 項研究
Salt Lake City 的其他研究
- 非小細胞肺癌31 項研究
- 癌症（所有類型）27 項研究
- 乳癌27 項研究
- 大腸直腸癌22 項研究
- 肺癌21 項研究
- 黑色素瘤21 項研究
- 多發性骨髓瘤21 項研究
- 轉移性癌症20 項研究
- 卵巢癌19 項研究
- 肥胖症18 項研究
- 急性髓系白血病17 項研究
- 心臟衰竭17 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。